menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Zerun Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zerun Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Zerun Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zerun Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zerun Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Shanghai Zerun Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zerun Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zerun Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of Witwatersrand, South Africa","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH AFRICA","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"University of Witwatersrand, South Africa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pill","sponsorNew":"University of Witwatersrand, South Africa \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"University of Witwatersrand, South Africa \/ Merck & Co"},{"orgOrder":0,"company":"Xiamen University","sponsor":"Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Xiamen University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen University \/ Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen University \/ Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China"},{"orgOrder":0,"company":"Shanghai Bovax Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Bovax Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Bovax Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Bovax Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"BravoVax","sponsor":"Shanghai BravoBio Co., Ltd. | Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BravoVax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BravoVax \/ Shanghai BravoBio Co., Ltd. | Novotech","highestDevelopmentStatusID":"6","companyTruncated":"BravoVax \/ Shanghai BravoBio Co., Ltd. | Novotech"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Innovax Biotech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Innovax Biotech \/ Undisclosed"},{"orgOrder":0,"company":"International Agency for Research on Cancer","sponsor":"University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Agency for Research on Cancer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Agency for Research on Cancer \/ University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer","highestDevelopmentStatusID":"10","companyTruncated":"International Agency for Research on Cancer \/ University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer"}]

    Find Clinical Drug Pipeline Developments & Deals for Human Papillomavirus Vaccine

    Menu

    Human Papillomavirus Vaccine

    DEVELOPMENTS

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xiamen Innovax Biotech

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of One Dose of HPV Vaccine

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 03, 2024

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BravoVax

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BravoVax

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Shanghai BravoBio Co., Ltd. | Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Clinical Trial of a Candidate HPV Vaccine

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 05, 2023

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Shanghai BravoBio Co., Ltd. | Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            International Agency for Research on Cancer

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            International Agency for Research on Cancer

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 29, 2021

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ISA Pharmaceuticals

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ISA Pharmaceuticals

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

                            Details : ISA101b is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 21, 2020

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Zerun Biotech

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shanghai Zerun Biotech

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 03, 2019

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ISA Pharmaceuticals

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ISA Pharmaceuticals

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

                            Details : ISA101b is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 13, 2018

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shanghai Bovax Biotechnology Co., Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shanghai Bovax Biotechnology Co., Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of Quadrivalent HPV Recombinant Vaccine

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 21, 2017

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shanghai Zerun Biotech

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shanghai Zerun Biotech

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 15, 2016

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Witwatersrand, South Africa

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Witwatersrand, South Africa

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervi...

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Dysplasia.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 23, 2013

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Xiamen University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Xiamen University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Dysplasia.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 28, 2012

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth